# OnCo record paper-oreilly-gemcitabine-cisplatin-veliparib-gbrca-palb2-pancreatic-jco-2020 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-oreilly-gemcitabine-cisplatin-veliparib-gbrca-palb2-pancreatic-jco-2020/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-oreilly-gemcitabine-cisplatin-veliparib-gbrca-palb2-pancreatic-jco-2020" ;
  schema:name "O'Reilly 2020: gemcitabine and cisplatin with or without veliparib in pancreatic cancer with a germline BRCA or PALB2 mutation"@en ;
  schema:description "In the first randomised trial restricted to pancreatic cancer patients with inherited BRCA or PALB2 mutations, platinum chemotherapy shrank tumours in about two-thirds and gave unusually long survival, while adding the PARP inhibitor veliparib to the chemotherapy did not help and added toxicity."@en ;
  schema:url <https://onco.cc/key-papers/paper-oreilly-gemcitabine-cisplatin-veliparib-gbrca-palb2-pancreatic-jco-2020/> ;
  schema:dateModified "2026-09-21"^^xsd:date ;
  schema:citation <https://doi.org/10.1200/JCO.19.02931>, <https://pubmed.ncbi.nlm.nih.gov/31976786/> ;
  schema:sameAs <https://doi.org/10.1200/JCO.19.02931> ;
  schema:datePublished "2020"^^xsd:gYear ;
  schema:author "O'Reilly EM, Lee JW, Zalupski M, et al." ;
  onco:cancers <https://onco.cc/cancers/brca-palb2-pdac/>, <https://onco.cc/cancers/pancreatic/> ;
  onco:drugs <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/cisplatin/> ;
  onco:people <https://onco.cc/people/eileen-oreilly/> ;
  onco:journals <https://onco.cc/journals/jco/> .